Cure51 focuses on extraordinary patients.
the Exception
that proves
the rule.
Our exceptional survivor community is a living proof that nature can beat Cancer.
NEWS
They talk
about CURE51
UntilAllSurvive.com: where cancer survivors share their inspiring stories
UntilAllSurvive.com: our brand new website featuring captivating exceptional cancer survivor journeys
How Patient Diversity in Clinical Trials Improves Cancer Research
Patient Population diversity is essential to discovering the biology of exceptional cancer survival
JOSEP TABERNERO, MD, PhD
Director Vall d’Hebron Institute of Oncology, Barcelona

FABRICE ANDRÉ, MD, PhD
President Elect ESMO Research Director Institut Gustave Roussy, Villejuif

OLIVIER ELEMENTO, PhD
Director of Englander Institute for Precision Medicine at Cornell University, NY

LOUIS DE MESTIER, MD
Principal Investigator Hopital Beaujon, AP-HP, Paris

PAN-CHYR YANG, MD, PhD
Principal Investigator National Taiwan University Hospital (NTUH)

NELSON DUSETTI, PhD
Research Director, INSERM | Pancreatic Cancer & Translational Oncology

SCOTT KOPETZ, MD
Head of Colorectal Cancer Moonshot programs MD Anderson, Houston

SOLANGE PETERS, MD, PhD
Head of Medical Oncology CHUV Lausanne

ULRICH KEILHOLZ, MD, PhD
LEAD SCLC, Director Charité Comprehensive Cancer Center Berlin
JEAN-YVES BLAY, MD, PhD
President UniCancer & Director Centre Léon Bérard, Lyon



























